I continue to believe that one of the best ways for investors to grow their wealth is to make long term investments in quality shares with strong business models and positive outlooks.
Three shares that tick a lot of boxes for me are listed below. Here’s why I think they could provide outsized returns for their shareholders over the next decade:
Altium Limited (ASX: ALU)
The first growth share that I would buy is electronic design software company Altium. Due to its key Altium Designer product and its exposure to the rapidly growing Internet of Things and artificial intelligence markets, I believe it is well-positioned to grow its revenue and earnings at solid rate over the coming years. Management certainly believes this will be the case. It remains confident the company will achieve its target of US$500 million in revenue, 100,000 subscriptions, and market domination. And while this appears likely to be a touch later than its original target of FY 2025 because of the pandemic, I’m very confident it will get there. Especially given the early success of its Altium 365 cloud-based offering and its other growing businesses such as NEXUS and Octopart.
Appen Ltd (ASX: APX)
Another growth share to consider buying is Appen. It is the global leader in the development of high-quality, human-annotated training data for machine learning and artificial intelligence. Appen has a massive team of 1 million+ crowd-sourced workers across the globe helping to improve the artificial intelligence models of many of the biggest tech companies in the world. Given the growing importance of artificial intelligence and machine learning and Appen’s leadership position in its field, I feel it is well-placed to continue growing its earnings at a strong rate in the 2020s.
ResMed Inc. (ASX: RMD)
A final growth share to consider buying is ResMed. I think the sleep treatment-focused medical device company is well-positioned for growth in the coming years thanks to its industry-leading products, growing ecosystem of connected devices, and its sizeable market opportunity. Management estimates that there are 936 million people with sleep apnoea globally and 380 million people suffering from chronic obstructive pulmonary disease (COPD). This gives it a significant runway for growth.
These stocks could rocket in a Post-COVID world (FREE STOCK REPORT)
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
Find out the names of our 3 Post COVID Stocks – For FREE!
*Returns as of 6/8/2020
More reading
- Top brokers name 3 ASX 200 shares to buy today
- Is the Altium share price a buy?
- The Appen share price just soared to an all-time high. Is it a buy?
- Nextdc and 2 other thriving ASX tech shares to buy
- ASX 200 drops 0.8%, JB Hi-Fi jumps 4.5%
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Altium. The Motley Fool Australia owns shares of Appen Ltd. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post 3 stellar ASX growth shares to buy in FY 2021 appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/2QaynVq
Leave a Reply